Prof. Dr. Lothar Häberle

Department of Obstetrics and Gynaecology Medizinische Fakultät

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany (2020) Hübner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Journal article Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial (2020) de Gregorio A, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, et al. Journal article Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment (2020) Würfel F, Hübner H, Häberle L, Gaß P, Hein A, Jud S, Hack C, et al. Journal article Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article Piwi-like 1 and piwi-like 2 expression in breast cancer (2020) Erber R, Meyer J, Taubert H, Fasching P, Wach S, Häberle L, Gaß P, et al. Journal article Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution Mammographic Density and Prognosis in Patients with primary Breast Cancer - Loss of Risk with increasing Age (2020) Heindl F, Fasching P, Hein A, Hack C, Heusinger K, Gaß P, Schulz-Wendtland R, et al. Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts (2020) Giardiello D, Hauptmann M, Steyerberg EW, Adank MA, Akdeniz D, Blom JC, Blomqvist C, et al. Journal article